ADMA vs GRFS

For growth investors, ADMA Biologics, Inc.

(ADMA) is the stronger pick with 19. 6% revenue growth year-over-year, versus 0. 2% for Grifols, S. A. (GRFS). Grifols, S. A. (GRFS) offers the better valuation at 12. 1x trailing P/E (9. 4x forward), making it the more compelling value choice. Analysts rate ADMA Biologics, Inc. (ADMA) a "Buy" — based on 10 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Grifols, S.

A. (GRFS) is the cheapest at 12. 1x versus ADMA Biologics, Inc. at 13. 6x. On forward P/E, Grifols, S. A. is actually cheaper at 9. 4x.

Over the past 5 years, ADMA Biologics, Inc.

(ADMA) delivered a total return of +389. 2%, compared to -53. 6% for Grifols, S. A. (GRFS). Over 10 years, the gap is even starker: ADMA returned +34. 8% versus GRFS's -35. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Grifols, S.

A. (GRFS) is the lower-risk stock at 1. 10β versus ADMA Biologics, Inc. 's 1. 25β — meaning ADMA is approximately 14% more volatile than GRFS relative to the S&P 500. On balance sheet safety, ADMA Biologics, Inc. (ADMA) carries a lower debt/equity ratio of 17% versus 115% for Grifols, S. A. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), ADMA Biologics, Inc.

(ADMA) is pulling ahead at 19. 6% versus 0. 2% for Grifols, S. A. (GRFS). On earnings-per-share growth, the picture is similar: Grifols, S. A. grew EPS 147. 8% year-over-year, compared to -25. 9% for ADMA Biologics, Inc.. Over a 3-year CAGR, ADMA leads at 49. 0% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

ADMA Biologics, Inc.

(ADMA) is the more profitable company, earning 28. 8% net margin versus 5. 3% for Grifols, S. A. — meaning it keeps 28. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ADMA leads at 37. 5% versus 16. 4% for GRFS. At the gross margin level — before operating expenses — ADMA leads at 57. 4%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Grifols, S.

A. (GRFS) trades at 9. 4x forward P/E versus 9. 7x for ADMA Biologics, Inc. — 0. 3x cheaper on a one-year earnings basis.

In this comparison, GRFS (2.

6% yield) pays a dividend. ADMA does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Grifols, S.

A. (GRFS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 10), 2. 6% yield). Both have compounded well over 10 years (GRFS: -35. 2%, ADMA: +34. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: ADMA is a small-cap high-growth stock; GRFS is a small-cap deep-value stock. GRFS pays a dividend while ADMA does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.